TCGA-D8-A1X7-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 17
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.490
- TGF_BETA_SIGNALING+0.420
- MTORC1_SIGNALING+0.300
- HEME_METABOLISM+0.280
- ANDROGEN_RESPONSE+0.270
- MITOTIC_SPINDLE+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.240
- FATTY_ACID_METABOLISM+0.230
- UV_RESPONSE_DN+0.230
- BILE_ACID_METABOLISM+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.460
- INTERFERON_GAMMA_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.360
- KRAS_SIGNALING_DN-0.230
- TNFA_SIGNALING_VIA_NFKB-0.190
- UV_RESPONSE_UP-0.190
- APICAL_SURFACE-0.180
- IL2_STAT5_SIGNALING-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A1AV-01A-21R-A12P-07 | — | B | 0.829 |
| 2 | MNG730 | — | — | 0.793 |
| 3 | TCGA-AN-A0FZ-01A-11R-A034-07 | — | B | 0.774 |
| 4 | SRR25617914 | — | C | 0.760 |
| 5 | R325 | — | — | 0.759 |
| 6 | TCGA-BH-A0BS-01A-11R-A12P-07 | — | B | 0.755 |
| 7 | TCGA-AC-A23H-01A-11R-A157-07 | — | C | 0.750 |
| 8 | MNG1056 | — | — | 0.748 |
| 9 | MNG1026 | — | — | 0.744 |
| 10 | TCGA-E2-A15L-01A-11R-A12D-07 | — | B | 0.743 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.490 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.280 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |